Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...
PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...
Hosted on MSN3d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationFintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
Camp4 Therapeutics Corporation’s CAMP share price has dipped by 18.47%, which has investors questioning if this is right time to buy.
Camp4 Therapeutics Corporation’s CAMP share price has surged by 18.71%, which has investors questioning if this is right time to sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback